These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 29103672)
1. Effects of Ivacaftor in Three Pediatric Siblings With Cystic Fibrosis Carrying the Mutations G551D And F508del. Mainz JG; Arnold C; Hentschel J; Tabori H Arch Bronconeumol (Engl Ed); 2018 Apr; 54(4):232-234. PubMed ID: 29103672 [No Abstract] [Full Text] [Related]
2. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy. Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004 [TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies. McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001 [TBL] [Abstract][Full Text] [Related]
4. [Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation]. Gomez-Pastrana D; Nwokoro C; McLean M; Brown S; Christiansen N; Pao CS An Pediatr (Engl Ed); 2019 Mar; 90(3):148-156. PubMed ID: 30093322 [TBL] [Abstract][Full Text] [Related]
5. Ivacaftor and Airway Inflammation in Preschool Children with Cystic Fibrosis. McNally P; Butler D; Karpievitch YV; Linnane B; Ranganathan S; Stick SM; Hall GL; Schultz A Am J Respir Crit Care Med; 2021 Sep; 204(5):605-608. PubMed ID: 34077699 [No Abstract] [Full Text] [Related]
6. Cystic Fibrosis: The Dawn of a New Therapeutic Era. Heltshe SL; Cogen J; Ramos KJ; Goss CH Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011 [No Abstract] [Full Text] [Related]
7. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation. Trimble AT; Donaldson SH J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142 [TBL] [Abstract][Full Text] [Related]
8. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL; N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692 [TBL] [Abstract][Full Text] [Related]
9. Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype. Terlizzi V; Amato F; Castellani C; Ferrari B; Galietta LJV; Castaldo G; Taccetti G Mol Genet Genomic Med; 2021 Apr; 9(4):e1656. PubMed ID: 33713579 [TBL] [Abstract][Full Text] [Related]
10. The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review. Dryden C; Wilkinson J; Young D; Brooker RJ; Arch Dis Child; 2018 Jan; 103(1):68-70. PubMed ID: 27288428 [TBL] [Abstract][Full Text] [Related]
11. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation. Bernarde C; Keravec M; Mounier J; Gouriou S; Rault G; Férec C; Barbier G; Héry-Arnaud G PLoS One; 2015; 10(4):e0124124. PubMed ID: 25853698 [TBL] [Abstract][Full Text] [Related]